EstherVinarov

Associate

Boston + 1.617.449.6926

Esther Vinarov represents hospitals, health systems, academic medical centers, digital health companies, physician group practices, pharmaceutical and medical device manufacturers, health care staffing agencies, and various other health care and life sciences companies.

Esther advises life sciences clients on issues associated with clinical research and the regulation of food, drugs, and medical devices by the Food and Drug Administration (FDA), including product promotion and advertising, good manufacturing practices, product recalls, FDA inspections, and enforcement actions. She provides regulatory and transactional due diligence support in food and life sciences M&A and other transactions and is involved in structuring various management service agreements and other arrangements to provide professional, practice management, or administrative services.

Esther counsels clients on regulatory and compliance issues, including direct-to-consumer telemedicine and telehealth, professional licensure, remote supervision, controlled substance prescribing, state corporate practice of medicine doctrines, and HIPAA (Health Insurance Portability and Accountability Act).

Esther maintains an active pro bono practice, representing clients in juvenile immigration proceedings and counseling various 501(c)(3) nonprofit organizations.

Esther is a member of the American Health Law Association and the Boston Bar Association.

Prior to attending law school, Esther studied clinical translation at a biomedical ethics research lab at McGill University. Her specific research focus was the impact of precision medicine on novel drug development in cancer.

Esther is coauthor of articles on oncology, drug developments in cancer, biomarker studies, and neurology that have appeared in leading medical journals.

Experiência

  • Reneo Pharmaceuticals announces reverse merger with OnKureJones Day is representing Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) in an all-stock reverse merger between Reneo and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company valued at $170 million that is focused on the development of novel precision medicines in oncology.
  • Nurse staffing agency resolves civil AG investigation in MassachusettsJones Day helped a national health care staffing agency negotiate a favorable resolution of an investigation by the Massachusetts Office of the Attorney General into the company's compliance with Massachusetts rate cap regulations for nursing facilities.
  • MEDHOST sells company to N. Harris Computer CorporationJones Day advised MEDHOST, Inc., a leading electronic health record solution provider, in its sale of the company to N. Harris Computer Corporation, a wholly-owned subsidiary of Constellation Software, Inc.
  • EagleTree Capital acquires Summit Hill FoodsJones Day advised EagleTree Capital in the acquisition and financing of Summit Hill Foods, Inc., a leading branded food company producing nationally recognized, premium brands, including Better Than Bouillon and The Original Louisiana Hot Sauce.
  • University of Pittsburgh Medical Center merges with Washington Health Care ServicesJones Day is acting as due diligence counsel to the University of Pittsburgh Medical Center in the merger with Washington Health Care Services.
  • restor3d acquires Conformis, Inc.Jones Day advised restor3d, Inc., a leading personalized 3D-printed orthopedic company, on its acquisition of Conformis, Inc. (NASDAQ: CFMS), a leading medical technology company focused on orthopedic patient care.
  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • KKR acquires IVI-RMA GlobalJones Day acted as U.S. counsel in the €3 billion acquisition of IVI-RMA, a group specialized in assisted reproduction techniques.
  • Organon makes strategic investment in Claria MedicalJones Day advised Organon in the strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
  • Leading financial services company provides financing in connection with strategic acquisition by private-equity sponsors of transportation services companyJones Day represented a leading financial services company, as left lead arranger and administrative agent, in a syndicated senior secured multi-currency revolving credit, term loan, and letter of credit facility, in connection with a strategic acquisition by private-equity sponsors of a transportation services company.
  • Morgan Stanley Capital Partners portfolio company acquires Labeltronix, LLCJones Day advised Morgan Stanley Capital Partners in connection with the acquisition by portfolio company AWT Labels & Packaging, Inc. (AWT) of Labeltronix, LLC, a leading label manufacturer of premium craft labels serving some of the country's most prominent brands, in a variety of markets including wine and spirits, craft beer, nutraceutical, food and beverage, and other CPG sectors.